预防性抗病毒药物可以减少登革热发病率在高患病率的特有地区吗?
Yalda Jafari1,2, Oliver J Brady1,2, Joseph R Biggs3
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
PLoS neglected tropical diseases
|July 29, 2024
概括
预防性药物和有针对性的干预措施可以显著减少登革热病例. 预防性大规模药物分发在疫情早期实施以控制登革热传播时最有效.
科学领域:
- * 流行病学和疾病控制
- * 传染病的数学建模.
- * 公共卫生干预措施
背景情况:
- *登革热在越南等流行地区构成了重大公共卫生挑战.
- * 在 Nha Trang 市的高血清流行率 (89.7%) 表明先前的登革热暴露范围广泛.
- * 预防药物的开发为登革热预防提供了新的途径.
研究的目的:
- *评估预防药物和各种干预策略对登革热爆发的潜在影响.
- * 为了比较病例区域向干预 (CATI) 和一次性大规模分发 (OTMD) 的有效性.
- * 评估预防性与反应性策略在登革热控制中的作用.
主要方法:
- *利用社区一级登革热传播调查来评估先前的暴露.
- * 开发并应用一个空间显式模型来模拟疫情情情景.
- *模拟了药物和载体控制策略的有效性,包括CATI和OTMD.
主要成果:
- *针对病例区域的有针对性的干预措施 (CATI) 当实施时具有更大的半径,更高的有效性和更短的延迟时最有效.
- * 预防性药物在预防登革热病例方面表现出更高的有效性,而不是载体控制措施.
- * 一次性大规模分发 (OTMD) 在早期启动时,每次避免病例需要更少的治疗,突出其作为预防策略的潜力.
结论:
- * 预防性干预,特别是预防性药物的早期OTMD,可以大幅减少登革热爆发的负担.
- *优化CATI参数 (半径,有效性,延迟) 提高了它们对登革热传播的影响.
- *研究结果支持考虑在流行地区有效控制登革热的预防性策略.
相关概念视频
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


